Treating Psoriasis: Simple Introduction about Acitretin and Tacrolimus
DOI:
https://doi.org/10.61173/2ypce089Keywords:
- psoriasis, keratinocytes, acitretin, tacrolim-us, cytokinesAbstract
Psoriasis is a skin infection disease that is related to dysfunction of the immune system. Plaque psoriasis is a common and typical psoriasis; it can be triggered by multiple factors, for example, environmental triggers and genetic factors. Skin with plaque psoriasis can be itchy and red, appear inflamed, and have scaly patches; the infected region can last for months and may leave permanent pigmentation. Keratinocytes (skin cells) are related to psoriasis; as homeostasis is disturbed, excess keratinocytes are produced, and surplus skin cells lead to psoriasis. Acitretin and tacrolimus are both drugs that can help with psoriasis but with different mechanisms.
References
[1] Available from: http://psoriasis.org
[2] Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985;121:1297–301.
[3] Available from: https://www.geeksforgeeks.org/human-skinstructure-function/
[4] Available from: https://www.nature.com/articles/492S50a
[5] Weinstein, GD, McCullough, JL, Ross, PA. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985; 85: 579–83.
[6] Chai Sue Lee & Kai Li, A review of acitretin for the treatment of psoriasis University of California Davis Medical Center, Department of Dermatology, 3301 C Street, Suite 1400, Sacramento, CA 95816, USA
[7] Fierlbeck, G, Rassner, G, Muller, C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immune histologic investigations. Arch Dermatol 1990; 126: 351–5.
[8] Teunissen, MB, Koomen, CW, De Waal Malefyt, R et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645–9.
[9] Lee, C. S., & Li, K. (2009). A review of acitretin for the treatment of psoriasis. Expert Opinion on Drug Safety, 8(6), 769–779.
[10] Chambon P. The retinoid signaling pathway: molecular and genetic analysis. Semin Cell Biol 1994;5:115-25
[11] Saurat JH. Retinoids: 10 Years On/ Retinoid Symposium. Switzerland: S Karger Pub, 1991
[12] Weinstein GD, Gottlieb AB. Therapy of Moderate-to-Severe Psoriasis. New York: Marcel Dekker, 2003.
[13] Sadaba, B., et al., [Treatment with tacrolimus in autoimmune diseases]. Revista de medicina de la Universidad de Navarra, 2003. 48(3): p. 24-38.
[14] Assman T, HomeyB, Ruzicka T. Application softacrolimus for the treatment of 2000;47:203-13. skin disorders. Immunopharmacology
[15] Paller, A., et al., A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 2001. 44(1): p. S47-S57.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
